New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;FB;PMFG From The Last 14 Days
Check below for free stories on BMY;FB;PMFG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
July 14, 2014
09:36 EDTFBActive equity options trading on open
Subscribe for More Information
09:25 EDTFBGoogle looked to Page, Brin to woo Facebook workers, WSJ says
Subscribe for More Information
07:22 EDTFBFacebook poised to report stronger than expected Q2 results, says Oppenheimer
Subscribe for More Information
July 11, 2014
15:59 EDTFBOptions Update; July 11, 2014
iPath S&P 500 VIX Short-Term Futures down 33c to 28.25. Option volume leaders: AAPL C GILD X FB GOOG AMZN TWTR TSLA according to Track Data.
09:37 EDTFBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL WFC C SUNE FB AMZN TSLA TWTR
07:42 EDTFBFacebook should move higher on strong quarter, says Deutsche Bank
Subscribe for More Information
06:10 EDTFBJPMorgan expects solid Q2 results in Internet space
Subscribe for More Information
July 10, 2014
16:00 EDTFBOptions Update; July 10, 2014
Subscribe for More Information
12:53 EDTFBFacebook research practices investigated by Irish watchdog, WSJ says
Subscribe for More Information
12:43 EDTBMYBristol-Myers announces plans for Q3 submission of Opdivo BLA
Bristol-Myers Squibb announced earlier that, following discussions with the FDA, the company is planning a Q3 submission of a Biologics Licensing Application for Opdivo for previously treated advanced melanoma. This will mark the second tumor type for which Bristol-Myers Squibb has a regulatory submission underway for Opdivo in the U.S. “We continue to collaborate closely with the FDA on Opdivo and the planned submission in advanced melanoma represents an important step forward in our company’s commitment to deliver innovative treatment options for patients with cancer,” said Michael Giordano, MD, Head of Oncology Development, Bristol-Myers Squibb. The advanced melanoma BLA is based on data from Checkmate -037, a multinational, multicenter, randomized open-label Phase 3 trial evaluating Opdivo compared to dacarbazine or carboplatin/paclitaxel in patients with unresectable or metastatic melanoma who have been previously treated with Yervoy and, if BRAF-mutation positive, a BRAF inhibitor regimen. Bristol-Myers Squibb has proposed the name Opdivo, which, if approved by health authorities, will serve as the trade name for nivolumab.
11:26 EDTFBStocks with call strike movement; TWTR FB
Twitter (TWTR) July 42 call option implied volatility increased 11% to 54, Facebook (FB) August 72.5 call option implied volatility increased 5% to 53 according to IVolatility.
09:36 EDTFBActive equity options trading on open
Subscribe for More Information
July 9, 2014
16:01 EDTFBOptions Update; July 9, 2014
Subscribe for More Information
10:56 EDTFBEU questions rivals about Facebook's proposed WhatsApp buy, WSJ reports
Subscribe for More Information
09:59 EDTFBFacebook downgraded to Neutral from Buy at Tigress Financial
09:35 EDTFBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AA FB AMZN TSLA TWTR MU NFLX GG CELG
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use